Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KANGUROO pediatric vibegron study in neurogenic detrusor overactivity
2024-513995-16-00Phase 3Authorised
- Sponsor
- Sumitomo Pharma America
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, open-label, single-arm trial of vibegron in detrusor hyperreflexia (DH), sponsored by Sumitomo Pharma America. Primary endpoint: Change from baseline in maximum cystometric capacity at Study Week 32. Planned start Jul 2023; status: authorised.
02
Drugs
vibegron
03
Conditions
detrusor hyperreflexia (DH)
Beyond the preview
Go deeper on 2024-513995-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513995-16-00.